Bastion Asset Management Inc. Has $9.81 Million Stake in AngioDynamics, Inc. $ANGO

Bastion Asset Management Inc. increased its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 46.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 959,043 shares of the medical instruments supplier’s stock after buying an additional 304,217 shares during the quarter. AngioDynamics accounts for 4.6% of Bastion Asset Management Inc.’s portfolio, making the stock its 3rd biggest holding. Bastion Asset Management Inc.’s holdings in AngioDynamics were worth $9,810,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of AngioDynamics by 8.7% in the 1st quarter. Vanguard Group Inc. now owns 2,492,563 shares of the medical instruments supplier’s stock worth $23,405,000 after acquiring an additional 199,944 shares during the period. Armistice Capital LLC increased its position in shares of AngioDynamics by 140.1% during the first quarter. Armistice Capital LLC now owns 2,094,000 shares of the medical instruments supplier’s stock valued at $19,663,000 after purchasing an additional 1,222,000 shares during the period. Nuveen LLC acquired a new position in shares of AngioDynamics in the first quarter valued at $10,803,000. Pier Capital LLC lifted its position in AngioDynamics by 40.5% in the second quarter. Pier Capital LLC now owns 694,235 shares of the medical instruments supplier’s stock worth $6,887,000 after purchasing an additional 200,244 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in AngioDynamics by 25.1% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 486,778 shares of the medical instruments supplier’s stock worth $4,571,000 after purchasing an additional 97,725 shares during the period. Institutional investors and hedge funds own 89.43% of the company’s stock.

Insiders Place Their Bets

In other AngioDynamics news, CEO James C. Clemmer acquired 10,000 shares of AngioDynamics stock in a transaction on Thursday, October 9th. The shares were bought at an average price of $11.15 per share, with a total value of $111,500.00. Following the completion of the purchase, the chief executive officer owned 882,529 shares in the company, valued at $9,840,198.35. This trade represents a 1.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Lawrence T. Weiss bought 10,000 shares of the stock in a transaction dated Tuesday, October 21st. The stock was acquired at an average price of $11.81 per share, with a total value of $118,100.00. Following the completion of the purchase, the senior vice president owned 93,597 shares of the company’s stock, valued at $1,105,380.57. This represents a 11.96% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders acquired 20,890 shares of company stock worth $239,532. Insiders own 6.00% of the company’s stock.

Analysts Set New Price Targets

ANGO has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of AngioDynamics in a report on Wednesday, July 16th. Lake Street Capital started coverage on shares of AngioDynamics in a research note on Wednesday, July 16th. They issued a “buy” rating and a $24.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, October 8th. Canaccord Genuity Group lifted their price objective on AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a report on Friday, October 3rd. Finally, Wall Street Zen cut AngioDynamics from a “buy” rating to a “hold” rating in a report on Saturday, October 4th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, AngioDynamics has a consensus rating of “Moderate Buy” and an average price target of $19.33.

AngioDynamics Stock Down 1.5%

Shares of ANGO stock opened at $11.73 on Friday. The company has a market capitalization of $483.28 million, a P/E ratio of -15.04 and a beta of 0.74. AngioDynamics, Inc. has a 12-month low of $6.63 and a 12-month high of $13.50. The firm has a 50-day moving average price of $11.25 and a 200 day moving average price of $10.11.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.02. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The company had revenue of $75.71 million during the quarter, compared to analyst estimates of $72.69 million. During the same quarter last year, the business posted ($0.11) earnings per share. The company’s revenue was up 12.1% on a year-over-year basis. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. As a group, research analysts expect that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.